Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17015111 | 0.87 | KCNN4 (1.00) | KCNN4 | |
| SCHEMBL17015109 | 0.83 | KCNN4 (1.00) | KCNN4 | |
| SCHEMBL17015124 | 0.81 | KCNN4 (0.70) | KCNN4SMN1; SMN2 | |
| SCHEMBL17015086 | 0.79 | KCNN4 (1.00) | KCNN4 | |
| SCHEMBL5461421 | 0.78 | KCNN4 (0.65) | KCNN4SMN1; SMN2 | |
| SCHEMBL17015114 | 0.77 | KCNN4 (1.00) | KCNN4 | |
| SCHEMBL17015077 | 0.76 | KCNN4 (1.00) | KCNN4 | |
| SCHEMBL29499523 | 0.73 | TSHR (0.62) | KCNN4SMN1; SMN2 | |
| SCHEMBL29353647 | 0.73 | TSHR (0.62) | KCNN4SMN1; SMN2 | |
| SCHEMBL29261955 | 0.73 | TSHR (0.62) | KCNN4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533999-B2 | Fused thiazin-3-ones as KCA3.1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-03 | — | — | US | disclosed |
| US-20150232484-A1 | FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-20 | — | — | US | disclosed |
| US-20150232484-A1 | FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232484-A1 | FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS | KCNA3, KCNK3, KCNN3 | KCNN4 76/4885SMN1; SMN2 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.